ロイエースタクス

PROF.KROCZEK, RKI

Express Mail No.: Hand Delivery

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Richard Kroczek

Confirmation No.: 7620

Application No.: 09/509,283

Group Art Unit: 1644

Filed: August 11, 2000

Examiner: J. Roark

For:

ANTI-HUMAN COSTIMULATING T-CELL

Attorney Docket No.: 7853-215

POLYPEPTIDE MONOCLONAL

ANTIBODIES

STATEMENT OF APPLICANT REGARDING PERMANENCE AND AVAILABILITY OF DEPOSITED MICROORGANISMS

Assistant Commissioner for Patents Washington, DC 20231 ·

Sir:

I, Richard Kroczek, Applicant of the above-identified application, declare and state:

That hybridoma 8F4, secreting native monoclonal antibody 8F4, was deposited with the Deutsche Sammlung Von Mikroorganismen und ZeliKulturen GmbH ("DSMZ"), at Mascheroder Weg 1b, D-3300 Braunschweig, Germany, on April 9, 2002, in compliance with the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure on my own behalf and on the behalf of the Bundesrepublik Deutschland, letztvertreten durch den Direktor des, Robert-Koch-Institutes, having a place of business at Nordufer 20, D-13353 Berlin, Germany, present assignce of the application. The

NY2 - 1359333.2

PROF. KROCZEK, RKI

5.03

deposited hybridoma was assigned DSMZ accession number DSM ACC2539. A copy of the Receipt of Deposit is attached hereto as Exhibit 1.

- That I participated in and supervised the production and maintenance of the hybridoma designated SF4 which was deposited with the DSMZ on April 9, 2002 and assigned DSMZ accession number DSM ACC2539.
- 3. That I confirm and corroborate that the hybridoma 8F4 deposited on April 9, 2002 with the DSMZ and assigned DSMZ accession number DSM ACC2539, which produces the monoclonal autibody 8F4, is the same hybridoma that was described in the specification of the above-identified application in Examples 1-8 at pages 11-19.
- 4. I hereby assure the United States Patent and Trademark Office and the public that

 (a) all restrictions on the availability to the public of the hybridoma referred to in paragraph I will be
 irrevocably removed upon issuance of a United States patent making reference to the hybridoma;

 (b) the hybridoma will be maintained for a period of at least five years after the most recent request
 for the furnishing of a sample of the deposited hybridoma was received by the DSMZ and, in any
 case for a period of at least 30 years after the date of deposit; (c) should the deposit become nonviable it will be replaced; and (d) access to the hybridoma will be available to the Commissioner
 during the pendency of the patent application or to one determined by the Commissioner to be
 entitled to the hybridoma under 37 C.F.R. § 1.14 and 35 U.S.C. § 122.

- 2 -

09:03

08-0KT-2002

PROF.KROCZEK, RKI

\$.04

5. I declare further that all statements made in this Declaration of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

Date Octo Soud Door

Richard Kroczek, M.D.

- 3 -

NY2 - 1349339.1

Exhibit 1

· 18-APR-2002 17:55

) PROF. KROCZEK, RKI

9.02

465174

INTERNATIONAL FORM

Robert Koch Institut Nordufer 20 13353 Berlin

1. Depositor		ie identification of the magnetification of the control of the con
Mine: Address:	Abbert Rich-lesitin Kürdüler 20 13353-Aerlin	Account comber gives to the contract of the co
	IVESTAGEMENT.	2002-04-09
. 60	ty of the ministriction of the control of the contr	X002-04-09 *-
TV: COND	ctions divide which the viablity testhas bein th	RPORMEDS.
,		
VENTER	NATIONAL DRECOSTIARY AUTHORITY	
Midren:	DSMZ:DELFISCRE SAMMEING YON MICROPRIANSMEN GND ZELLEULTUREN GmbH Einschnickei, Wag 18 D-38124 Britisch weig	Signature(s) of person(s) having the point to represent the international Depository Architecture and authorises or final (s); U. U. Lo Date: 2002-04-16

Indicate the flate of friginal disposition, where a new deposit of a transfer has been indeed, the most recent relevant data of the new deposit entire a transfer.

In the manufact.

In the manufact of the policy of the second of the most recent viability test.

Mark with decimalist applicable has.

Fill this the information has been requested and if the results of the new were negative.

Form DSMZ-BP/9 (mis-page) 12/2001



BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATE PATENT AND TRADEMARK OFFICE

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Dr. Abu-Shaar is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Pennie & Edmonds, LLP to prepare and prosecute patent applications wherein the patent applicant is the client of Pennie & Edmonds, LLP, and the attorney or agent of record in the applications is a registered practitioner who is a member of Pennie & Edmonds, LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Dr. Abu-Shaar ceases to lawfully reside in the United States, (ii) Dr. Abu-Shaar's employment with Pennie & Edmonds, LLP ceases or is terminated, or (iii) Dr. Abu-Shaar ceases to remain or reside in the United States on an H-1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: May 28, 2004

Harry I. Moatz

Director of Enrollment and Discipline